TITLE PAGE
TRIAL STATISTICAL AN ALYSIS PLAN
c22042336-05
BI Trial No.: 1245-0168
Title: A phase III randomised, double- blind trial to evaluate the effect of 
12 weeks treatment of once dail y EMPagliflozin 10 mg compared 
with placebo on ExeRcise ability  and heart failure sy mptoms, In 
patients with chronic HeArt FaiLure with r educed Ejection 
Fraction ( HFrEF) (EMPERI AL –reduced)
Revised protocol version 3.0 including Protocol Amendment 2
[c17550230
-03]
Investigational
Product(s):Empagliflozin
Responsible trial 
statistician (s):
Phone: 
Fax: 
Date of statistical 
analysis plan:[ADDRESS_914997] 2019 REVI SED
Version: REVI SED
Page 1of 63
Proprietary confidential information
2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved .
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 2of 63
Proprietary confidential information © [ADDRESS_914998] SETS ANALYSE D
...........................................................................18
6.4 SUBGROUPS ......................................................................................................19
6.5
POOLING OF CENTRES .................................................................................22
6.6 HANDLING OF MISSING 
DATA AND OUTLIERS ....................................22
6.6.1 Primary endpoint ................................................................................................23
6.6.2 Key Secondary endpoint .....................................................................................23
6.6.3 Secondary endpoints ...........................................................................................25
6.6.4 Longitudinal Analyses ........................................................................................26
6.6.5 Safety Analyses ....................................................................................................27
6.6.6 Missing dates ................................ ................................ ................................ .......27
6.7 BASELINE, TIME WINDO WS AND CALCULATED VI SITS ...................29
7. PLANNED ANALYSIS ......................................................................................32
7.1 DEMOGRAPHIC AND OTHE R BASELINE CHARACTER ISTICS .........
32
7.2 CONCOMITANT DISEASES AND MEDICATION .....................................33
7.3 TREATMENT COMPLIANCE ................................ ................................ ........33
7.4 PRIMARY ENDPOINT ................................ ................................ .....................33
7.4.1 Primary analysis of the primary endpoint ........................................................33
7.4.2 Sensitivity analysis of the primary endpoint ................................ ....................34
7.4.3 Subgroup analysis of the primary endpoint ................................ .....................34
7.5 SECONDARY ENDPOINTS ................................ ................................ .............34
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 3of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.5.1 Key secondary endpoints ....................................................................................34
[IP_ADDRESS] Primary  anal ysis of the key  secondary  endpoints
................................ .................35
[IP_ADDRESS] Sensitivity  analy sis of the key  secondary  endpoints .............................................35
[IP_ADDRESS] Subgroup anal ysis of the key  secondary  endpoints
..............................................35
[IP_ADDRESS] Further exploratory  anal yses of the key secondary  endpoints ..............................
36
7.5.2 Other Secondary endpoints ................................................................................36
7.6 FURTHER ENDPOINTS ...................................................................................37
7.6.1 Binary endpoints
.................................................................................................37
7.6.2 Ordinal endpoints ...............................................................................................37
7.6.3 Continuous endpoints .........................................................................................38
7.7 EXTENT OF EXPOSURE
.................................................................................39
7.8 SAFETY ANALYSIS ..........................................................................................39
7.8.1 Adverse events .....................................................................................................39
[IP_ADDRESS]
Assignment of AEs to treatment ................................ ................................ ...........39
[IP_ADDRESS] AE summaries .......................................................................................................40
[IP_ADDRESS] Adverse events of special interest (AESIs) ...........................................................41
[IP_ADDRESS] Specific AEs ..........................................................................................................42
[IP_ADDRESS] Events qualify ing for external adjudication by  [CONTACT_247664] ........
44
[IP_ADDRESS] AEs while patients taking wrong medication .......................................................45
[IP_ADDRESS] Adverse event incidence rates ...............................................................................45
7.8.2 Laboratory data ..................................................................................................46
7.8.3 Vital signs .............................................................................................................49
7.8.4 ECG and physical examination .........................................................................49
7.8.5 Others ...................................................................................................................49
8. REFERENCES ....................................................................................................50
9. ADDITIONAL SECTIONS ...............................................................................51
9.1 REGION S AND COUNTRIES ..........................................................................51
9.2 DIABETES STATUS AT B ASELINE ..............................................................52
9.3 DERIVATION OF RESPON DER THRESHOLD FOR KC CQ-TSS AND 
CHQ
-SAS DYSPNEA .........................................................................................53
9.4 DERIVATION OF KCCQ AND CHQ -SAS DOMAINS ................................
54
9.4.1 Kansas City Cardiomyopathy Questionnaire (KCCQ) ...................................54
9.4.2
Chronic Heart Failure Questionnaire (CHQ) Self- Administered 
Standardised format (SAS) ................................................................................60
9.5
DERIVATION OF CLINICAL CONGESTION SCORE .............................. 60
10. HISTORY TABLE ..............................................................................................62
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 4of 63
Proprietary confidential information © [ADDRESS_914999] OF TABLES
Table 6.1: 1 Treatment regimens / study  intervals ................................ ...............................13
Table 6.1: 2 Endpoint -
specific assignment to the on-treatment phase................................ .14
Table 6.2: 1 Important protocol deviations ..........................................................................14
Table 6.3: [ADDRESS_915000] sets anal ysed........................................................................................19
Table 6.4: 1 Categories of covariates for display s of baseline characteristics and 
subgroup anal yses............................................................................................20
Table 6.6.2: 1 Imputation Rules for missing KCCQ
-TSS Assessments at Week 12 ..............24
Table 6.6.2: 2 Imputation Rules for missing CHQ -SAS Assessments at Week 12 ................25
Table 6.6.3: 1 Imputation rules for missing exercise capacity  at week 6 ................................26
Table 6.7: 1 Time windows for primary  anal ysis of primary  and key  secondary  
endpoints and Sensitivity  anal yses using Wilcoxon model .............................30
Table 6.7: 2 Time windows for measurements except primary  analy sis of primary  and 
key secondary  endpoints [OC -OT] ..................................................................30
Table 6.7: 3 Time windows for measurements except primary  analy sis of primary  and 
key secondary  endpoints [OC -AD] ..................................................................31
Table 7.8.2: 1 CKD staging
.....................................................................................................48
Table 9.1: 1
Regions and countries ......................................................................................51
Table 9.2: 1 DM at baseline ................................ ................................ ................................ .52
Table 10: 1 History  table .....................................................................................................62
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 5of 63
Proprietary confidential information © [ADDRESS_915001] OF ABBREVIATIONS
Term Defini tion / description
6MWT Six-minute walking test
6MWTD Six-minute walking test distance
ACE Angiotensin converting enzy me
AE Adverse Event
AESI Adverse Event of Special Interest
ALT Alanine transaminase
ANCOVA Analy sis of covariance
ARB Angiotensin Receptor Blocker
ARNI Angiotensin Receptor -Neprily sin Inhibitor
ASA acetylsalicy lic acid
AST Aspartate transaminase
ATC Anatomical -Therapeutic -Chemical classification
AUC Area Under the receiver operating characteristic Curve
BI Boehringer Ingelheim
BIcMQ Boehringer Ingelheim customised MedDRA Query
BMI Body Mass Index
BP Blood Pressure
bpm beats per minute
BRPM Blinded Report Planning Meeting
CEC Clinical event committee
CHF Chronic Heart Failure
CHQ Chronic Heart Failure Questionnaire
CHQ -SAS Chronic Heart Failure Questionnaire -Self-Administered Standardised 
format
CKD Chronic Kidney  Disease
CKD -EPI [INVESTIGATOR_676633]: 1245-0168 Page 6of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Term Defini tion / description
CRA Clinical Research Associate
CV Cardiovascular
DBL Database lock
DBP Diastolic Blood Pressure
DKA Diabetic ketoacidosis
DM Diabetes Mellitus
DM&SM Boehringer Ingelheim Data Management And Statistics Manual
ECDF Empi[INVESTIGATOR_676634]-of- Text
gCV Geometric coefficient of variation
HF
HFrEF
HHFHeart Failure
Heart Failure with reduced Ejection Fraction
Hospi[INVESTIGATOR_676635] -Level Term
IC Informed Consent
ICH International Conference On Harmonisation
iPD Important Protocol Deviation
JVD Jugular Venous D istension
KCCQ Kansas City Cardiomy opathy  Questionnaire
KCCQ -CSS Kansas City  Cardiomy opathy  Questionnaire – Clinical Summary Score
KCCQ -TSS Kansas City  Cardiomy opathy  Questionnaire - Total Sy mptom Score
LLT Lowest Level Term
LVEF Left Ventricular Ejection Fraction
MedDRA Medical Dictionary  For Regulatory  Activities
MMRM mixed model repeated measure anal ysis
MRA Mineralocorticoid receptor antagonist
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 7of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Term Defini tion / description
NT-proBNP N-Terminal Pro -Brain Natriuretic Peptide
NYHA [LOCATION_001] Heart Association
OC-AD Observed Case including data After Discontinuation
OC-OT Observed Case On Treatment
PD Protocol Deviation
PDMAP Project Data Management and Anal ysis Plan
PGI-C Patient Global I mpression of Change
PGI-S Patient Global I mpression of Severity
PRO Patient Reported Outcome
PT Preferred Term
pt-yrs patient y ears
Q1 Lower Quartile
Q3 Upper Quartile
ROC Receiver Operating Characteristic
RS Randomised Set
SAE Serious Adverse Events
SBP Systolic Blood Pressure
SCR Screened Set
SD Standard Deviation
SE Standard Error
SEM Standard Error of Measurement
SensRS Sensitivity  analy sis set
SMQ Standardised MedDRA Query
SOC System Organ Class
T1DM Type [ADDRESS_915002] Case I mputation
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 8of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Term Defini tion / description
WHO DD World Health Organization Drug Dictionary
Y/N Yes/No
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 9of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
3. INTRODUCTION
As per ICH E9 (1), the purpose of this document is to provide a more technical and detailed 
elaboration of the principal features of the analysis described in the protocol, and to include 
detailed procedures for executing the statistical analysis of the primary and secondary 
variables and other data.
This TSAP assumes familiarity with the Clinical Trial Protocol (CTP), including Protocol 
Amendments. In particular, the TSAP is based on the planned analysis specification as 
written in CTP Section 7 “Statistical Methods and Determination of Sample Size”. Therefore, 
TSAP readers may consult the CTP for more background information on the study, e.g., on 
study objectives, study design and population, treatments, d efinition of measurements and 
variables, planning of sample size, randomi
sation.”
SAS®Version 9.4 will be used for all analyses.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 10of 63
Proprietary confidential information © [ADDRESS_915003] UDY
4.1 CHANGES NEWLY INTROD UCED FROM THE CLINIC AL TRIAL 
PROTOCOL
Analy ses of t he following endpoints ha vebeen added:
Systolic blood pressure 
Diastolic blood pressure
Body
weight
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 11of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
5. ENDPOINT S
5.1 P RIMARY ENDPOINT
The primary  endpoint is defined in CTP Section 2.1. 2.
5.2
SECONDARY ENDPOINT S
5.2.1 Key secondary endpoints
The key  secondary  endpoint is defined in CTP Section 2.1.3. The s coring algorithm for 
KCCQ -TSS and CHQ -SAS dy spnea can be found in Appendix 9.4.
5.2.2 Secondary endpoints
Secondary  endpoints are listed in CTP Section 2.1.3. The s coring algorithm for the clinical 
congestion score can be found in Appendix 9.5.
5.3 F URTHER ENDPOINT S
Further endpoints are listed in CTP Section 2.2.2.
Response in KCCQ domains at week 12: Response will be defined as an improvemen t of at 
least 5 points.
Response in CHQ domains at week 12: Response will be defined as an improvement of at 
least 0. 5points. Scoring algorithm for all KCCQ domains and CHQ- SAS domains can be 
found in Appendix 9.4.
5.4 O THER VARIAB LES
5.4.1 Demographic and other baseline characteristics
Blood pre ssure: Baseline SBP and DBP are taken from the vital signs assessment. If no vital 
signs assessment is available , the value before the start of the6MWT will be used .
Region will be defined according to Table 9.1:1
Heart rate will display  values enter edin the electronic case report form (eCRF ) as ‘pulse ’. 
5.4.2 Treatment compliance
Overall compliance (%)to study  medication will be calculated as a weighted average of 
reported compliance. Weights will be determined based on actual visit dates. Compliance wil l
be display ed for the treated set .
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 12of 63
Proprietary confidential information © [ADDRESS_915004] inta ke of study  drug –day of first 
intake of study  drug + 1 day . 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 13of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6. GENERAL ANALYSIS DEFI NITIONS
6.1 T REATMENT S
There will be 3 study  intervals in this trial: screening, study  treatment phase (with either 
empagliflozin 10mg or matching placebo) and follow -up. The purpose of the definitions 
below is to describe the different stud y intervals.
Table 6.1: 1 Treatment regimens / study  intervals
Label in database Label in tables 
and listingsInterval Start date 
SCREENI NG Screening Screening Date of informed consent
PLACEBO/
BI [ZIP_CODE] 10 MGPlacebo/Empa 
[ADDRESS_915005] Pbo/Post 
EmpaFollow up Date of last administration of 
study  drug + 1 day
Details on the definition of the treatment period for different endpoints are listed in 
Table 6.1:2 . The efficacy anal yses will follow the intention -to-treat (ITT) principle .For the
assignment of patients to treatment groups this means that patients will be anal ysed as 
randomised. 
For s afety anal yses, patients will bealso assign edto the treatment group sas randomi sed.
If a patient erroneously  receives the wrong trial drug, all future medication packs will be 
dispensed as scheduled for the treatment group to wh ich the patient was randomised. 
Therefore ,the adverse events will be anal ysed as per randomised treatment, which is 
expected to reflect the prevailing treatment. In e
xceptional case s that a patient took the wrong 
treatment, all adverse events that occur while being on the wrong treatment will be listed and 
analyses of this data are described in section [IP_ADDRESS]. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 14of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.1: [ADDRESS_915006] day  of assignment to 
on-
treatment phase
(days after last intake of study  
medication )
6MWT distance 1
PRO endpoints (key second ary endpoints ) 7
Adverse events 7
Safety  laboratory  measurements 3
Heart rate 1
Bodyweight 1
Creatinine and estimated glomerular filtration 
rate (eGFR)1
Blood pressure 1
6.2 I MPORTANT PROTOCOL DEVIATIONS
A protocol deviation (PD ) is important, if it affects the rights or safet y of the study patients or 
if it can potentially  influence the primary  outcome measures for the respective patients in a 
way that is neither negligible nor in accordance with the study  objectives. 
Important protocol deviations ( iPDs) will be described in the clinical trial report (CTR). A 
listing of patients with medication code broken will be provided.
Table 6.2: 1 Important protocol deviations
Category / 
CodeDescription Requirements Excluded 
from
A Entrance criteria not met
A1 Target indication not met
A1.06 No chronic HF or no NYHA 
class II -IVInclusion criterion #5 not met None
A1.07 Conditions on ejection 
fraction (EF) not metInclusion criterion #6 not met None
A1.08 Conditions on NT -proBNP 
not metInclusion criterion #7 not met None
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 15of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.2: 1 Important protocol deviations (cont.)
Category / 
CodeDescription Requirements Excluded 
from
A2/3 Other entrance criteria not 
met
A2.02 Age out of range Inclusion criterion #1 not me t None
A2.08 Specific inclusion criterion for 
women of child -bearing 
potential not metInclusion criterion #2 not met None
A2.14 6MWT distance above 350m 
at screening or baseline or 
below 100m at baselineInclusion criterion #4 or exclusion 
criterion #10 not metSensRS1
A2.12 Inclusion criterion on stable 
concomitant medication not 
metInclusion criterion #8 not met None
A2.13 Use of medical devices not 
appropriate or device 
implanted recently or intent to 
implantInclusion criterion #10 or exclusion 
criterion #18 not metNone
A3.44 Patient with unstable 
conditionsExclusion criteria #1, #2, #6. #9, #13, 
#17, #20, #21 or #25 not met, inclusion 
criterion #9 not metNone
A3.49 Participation in another 
Empagliflozin HF trialExclusion criterion #3 not met None
A3.51 Type 1 diabetes Exclusion criterion #4 not met None
A3.09 Renal insufficiency or renal 
impairment (assessed by 
[CONTACT_67889])Exclusion criterion #5 not met None
A3.33 Systolic blood pressure at visit 
1 or 2 out of rangeExclusion criterion #7 not met None
A3.31 Atrial fibrillation or atrial 
flutter with a resting heart rate 
>110bpm Exclusion criterion #8 not met None
A3.48 Presence of condition that 
precludes exercise testingExclusion criterion #11 not met None
A3.47 Participation in structured 
Exercise trainingExclusion criterion #[ADDRESS_915007] device 
(LVAD)Exclusion criterion #14 not met None
A3.29 Patients with 
cardiomyopathies excluded by 
[CONTACT_676650] #15 or #19  not met None
A3.30 Any severe (obstructive or 
regurgitant) valvular heart 
disease excluded by [CONTACT_676651] #16 not met None
A3.06 Indication of liver disease Exclusion criterion #22 not met None
A3.34 Haemoglobin at visit 1 below 
cut-offExclusion criterion #23 not met None
A3.35 History of Ketoacidosis Exclusion criterion #24 not met None
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 16of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.2: 1 Important protocol deviations (cont.)
Category / 
CodeDescription Requirements Excluded 
from
A3.36 Gastrointestinal (GI) surgery 
or GI disorder that could 
interfere with study 
medication absorption in the 
investigator’s opi[INVESTIGATOR_676636] #2 6not met None
A3.37 Documented or active 
malignancyExclusion criterion #[ADDRESS_915008] of the 
trialExclusion criterion #2 8  not met None
A3.40 Treatment with any SGLT -2 
inhibitor
or SGLT -1 and 2 inhibitorExclusion criterion #2 9not m et None
A3.50 Treatment with i.v. iron 
therapy or erythropoietin 
(EPO) within 3 months prior 
to screeningExclusion criterion #30 not met None
A3.11 Intake of an investigational 
drug in another trial within 30 
days prior to intake of study 
medication in this trialExclusion criterion #31 not met None
A3.41 Known allergy or 
hypersensitivity to
empagliflozinExclusion criterion #32 not met None
A3.13 Relevant alcohol or drug 
abuse and other conditions 
affecting study compliance Exclusion criterion #33 not met None
A3.12 Specific exclusion criterion 
for pre -menopausal women 
not metExclusion criterion #3 4not met None
A3.14 Any other clinical condition 
unsafe for participation that 
would jeopardise patient 
safety while participating in 
this clinical trialExclusion criterion #3 5not met None
B Informed consent
B1 Informed consent not 
available/not doneInformed consent date missing All
B2 Informed consent too late Informed consent date < actual consent 
date> was after Visit 1 date < Visit 1 
date>None
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 17of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.2: 1 Important protocol deviations (cont.)
Category / 
CodeDescription Requirements Excluded 
from
C Trial medication and 
randomisation
C1.[ADDRESS_915009] trial medication 
takenWrong medication taken for more than 
20% of the overall treatment duration. 
Can only be finally judged after data 
base lock (DBL) since unblinding 
information is required.None
C3.01 Non-compliance with study 
drug intakeCompliance <80% or >120% None
C4.011Medication code broken 
inappropriatelyMedication code was broken for no 
valid reason.
Final decision at the DBL meeting based 
on medical judgement. None
D Concomitant medication
D2.[ADDRESS_915010] 
been based on stoppi[INVESTIGATOR_3418], 6MWT 
not rescheduled appropriately when 
patient presents with relative 
contraindications SensRS1
G3.501Assessment order not 
followed that could influence 
PRO at baseline or week 12PRO measurements not before any other 
assessment at baseline or week 12None
I Other safety -related 
deviations
I2.01 Pregnancy None
KEY: 6MWT= six minute walk test, HF=Heart Failure, NT-proBNP= N-Terminal Pro -Brain Natriuretic Peptide , NYHA= 
[LOCATION_001] heart association, EF=ejection fraction, T1DM=Type 1 diabetes mellitus, bpm=beats per minute.
1
needs to be checked at site by [CONTACT_676652] (CMLs) / Clinical Research Associates (CRAs) as these cannot be 
checked programmatically
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 18of 63
Proprietary confidential information © [ADDRESS_915011] SETS ANALYSED
The following patient sets are defined in section 7.3 of the protocol:
•Randomised set (RS)
This patient set includes all randomise d patients, whether treated or not. Treatment 
will be evaluated as randomised.
•Treated set (TS)
This patient set includes all patients who were dispensed study medication and were 
documented to have taken at least one dose of investigational treatment. Treatment 
will be evaluated as randomised.
In addition the following patient set is defined:
•Screened Set (SCR)
Consists of all patients screened for the trial, with informed consent given and who 
completed at least one screening procedure at Visit 1.
For se nsitivity  anal yses the following patients set is defined:
•Sensitivity analy sis set 1 (SensRS1)
Randomised patients excluding patients with an iPD related to 6MWT, i.e. iPD 
categories A2.14, G3.48 and G3.49 of Table 6.2: 1
•Sensitivity  analy sis set 2 (SensRS2)
Randomised patients excluding patients for which at least one on -treatment value of 
urine glucose test result was included in the safety  laboratory  reports posted to a 
portal by  [CONTACT_2237] , and the reports w ere accessed before database lock.
•Sensitivity  analy sis set 3 (SensRS3)
Randomised patients excluding non -diabetic patients for which at least one on-
treatment value of urine glucose test result was included in the reports posted and 
accessed before databa se lock.
Demographics and baseline characteristics as well as t he efficacy  anal ysis will be based on 
the RS. 
Demographics will be repeated on the TS if the number of patients in the analysis sets 
differ b y more than 5%. T he safet y analysis will be based on the TS .
Overall number of patients participating in the study  (screened, randomi sed, screened but not 
randomi sed, etc.) b y region and country  will be based on the SCR.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 19of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.3: [ADDRESS_915012] set
Class of endpointScreened 
SetRandomised 
setTreated set
Primary and key secondary 
endpoints X X
(other) Secondary and further 
endpoints X
Safety endpoints X
Dem ographic/baseline 
endpointsX X1
Extent of exposure X
Disposition X
1Demographics will be repeated on the TS if the number of patients in the analysis sets 
differ b y more than 5%.
6.4 S UBGROUPS
Subgroups are provided in Table 6.4: 1 . Missing categories for subgroup variables will not be 
considered in the respective anal ysis. 
Subgroups with fewer than 14 patients in total (y ielding approximately  7 patients per 
treatment group) will generall y not be included in the anal yses of subgroup s. Small 
subgroups can be combined into other subgroups. Final de
cision will be made at final 
Blinded Report Planning Meeting (BRPM) .
Although several subgroup anal yses are prespecified in Table 6.4: 1, the subgroup anal ysis by  
[CONTACT_676653] (diabetic, non -diabetic) is the medically  and academically  most 
importan t subgroup analy sis.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 20of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.4: 1 Categories of covariates for displays of baseline characteristics and subgroup 
analyses
Variable Categori sation Dem o-
graphics1Subgroups for 
Efficacy 
endpoints2Safety
Age (years) <50
50 to <65
65 to <75
75 to <85
≥85X
< 65
≥65X X
Sex Male
FemaleX X
Region3Europe , Australia, North 
AmericaX
Europe or Australia
North AmericaX
Ethnicity Hispanic/ Latino
Not Hispanic/ LatinoX X
Race American Indian or Alaska 
Native
Asian
Black or African- American
Native Hawaiian or other 
Pacific Islander
WhiteX
White
Black/ African -American
Asian
Other including mixed raceX
BMI (kg/m2) <30
≥30X X
eGFR at baseline 
(mL/min/1.73m²)≥90
60 to <90
45 to <60
30 to <45
20 to <30
<20X
≥60 
45 to <60
30 to <45
<30X
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 21of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.4: 1 Categories of covariates for displays of baseline characteristics and subgroup 
analyses (cont.)
Variable Categorisation Dem o-
graphics1Subgroups for 
Efficacy 
endpoints2Safety
Diabetes at baseline4DM, 
pre-DM, 
non-DM(excl. pre- DM)X
DM, non -DM X X (only 
hypoglycemia)
History of hypertension Yes / No X
Baseline BP SBP<140 and DBP<90 vs. 
SBP≥ 140 or DBP≥90X X
Atrial Fibrillation at 
baseline5Yes/ No X X
Baseline LVEF <20, >=20 to <=30, >30 to 
<=35, >35 X X
History of valvular disease Yes / No X
Cause of HF Ischemic
Hypertensive
Valvular heart disease
Diabetic
Alcoholism
Idiopathic
Cardiomyopathy
OtherX
Time since diagnosis of HF ≤ 1 year, >1 to ≤ 5 years, > 5 
to ≤ 10years, > 10 yearsX
NYHA at baseline I/
II/III/IV X
II6vs. III/IV X
NT-proBNP (separated by 
[CONTACT_676654]) at 
baseline7atrial fibrillation at baseline 
and < / ≥ median;
no atrial fibrillation at 
baseline and < / ≥ median X
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 22of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.4: 1 Categories of covariates for displays of baseline characteristics and subgroup 
analyses (cont.)
Variable Categorisation Dem o-
graphics1Subgroups for 
Efficacy 
endpoints2Safety
Baseline KCCQ -TSS By [CONTACT_39125] X (only 
KCCQ- TSS 
and 6MWT)
Baseline CHQ -SAS 
Dyspnea domainBy [CONTACT_39125] X (only CHQ -
SAS dyspnea 
and 6MWT)
Baseline PGI -S Dyspnea 5 categories X X (only CHQ -
SAS dyspnea)
Baseline PGI -S HF 
symptoms5 categories X X (only 
KCCQ- TSS)
Baseline distance walked in 
6 minutes< / > = median X (only 
6MWT)
Baseline use of ACE -
inhibitor, ARB or ARNiYes / No X8X
Baseline use of diuretics 
other than MRAYes / No X8X
Baseline use of MRA Yes / No X8X
Baseline use of loop or 
high-ceiling diureticsYes / No X8X
baseline haemoglobin < / >= median X
1The column demographics shows categories display ed for overall demographics. 
Demographics are not planned b y subgroup. 
2Subgroups planned for the following endpoints: primary  and key secondary  endpoints. 
3Region categori sation: see Table 9.1: 1. 
4Diabetes at baseline categorisation: see Table 9.2: 1; for subgroup anal ysis ‘pre -DM’ and 
‘non-DM (excluding pre- DM) ’will be combined into the category  ‘non -DM’
[ADDRESS_915013] ECG before treatment intake
6 patients with NYHA class I are counted in subgroup NYHA class II
7Median NT -proBNP will be calculated for randomised patients with/without atrial 
fibrillation at baseline separatel y and subgroups will be defined based on the respective 
median for patients with/without atrial fibrillation at baseline accordingl y
8part of the presentation of baseline concomitant therap y as outlined in Section 7.2
6.5 P OOLING OF CENTRES
Notapplicable because centre/country is not included in the statistical model.
6.6 H ANDLING OF MISSING DATA AND OUTLIERS
The imputation strategy  for all confirmatory  anal yses, i.e. primary  anal ysis of primary and 
key secondary  endpoints, will be based on the following principle:
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 23of 63
Proprietary confidential information © [ADDRESS_915014] ers: Patients who do not have a clinical event (death, serious 
adverse event or an y AE leading to discontinuation) and have a value at week [ADDRESS_915015] a clinical event are given a lower rank and death is 
ranked below an y other clinical event b y time to death from randomisation. 
A treatment -emergent SAE wit h outcome “recovered with sequelae” leading to an 
amput ation is considered to be an ongoing clinical event.
Imputation will not be applied for an y parametric anal ysis, descriptive statistics and 
derivation of responder thresholds for the key  secondary  endpoints.
6.6.1 Primary endpoint
Handling of missing dat a is described in section 7.5 of the clinical trial protocol for the 
primary  anal ysis and subgroup anal ysis of the 
primary  endpoint change from baseline in 
6MWTD.
6.6.2 Key Secondary endpoint
Missing individual items within a questionnaire will be handle d according to the rules in
Appendix 9.4.
Patients with an available week 12 measurement, regardless of whether on or off treatment, 
will be ranked based on change from baseline at week 12 regardless of clinical events . 
For an y missing week 12 assessment of the KCCQ -TSS, the below imputation will be applied
for the primary  anal ysis and subgroup anal ysisin accordance to the strategy  for the primary  
endpoint:
Since the lowest possible value for change from baseline in KCCQ -TSS is [ADDRESS_915016] possible baseline value (100), all imputed values for change from baseline are 
below - 100 as described in Table 6.6.2: 1below.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 24of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.6.2: 1 Imputation Rules for missing KCCQ-TSS Assessments at Week 12
Categ ory Ranking Case description (Imputed) 
Change from 
baseline in 
KCCQ -TSS for 
described case 
1 Missing data on KCCQ -
TSS at week 12 and no 
clinical event:
Patients with missing 
KCCQ -TSS at week [ADDRESS_915017] 
available value
of x points, no 
clinical event-102 +x/[ADDRESS_915018] -baseline 
KCCQ -TSS and 
no clinical event -104
2 Missing data and 
clinical event (except 
death).
A clinical event is 
defined as ongoing SAE 
at week 12 or AE 
leading to treatment 
discontinuation and 
patient is alive at week 
12Ranke d above 
patients who died, 
but below patients 
with missing data 
and no clinical 
event.Patient has 
ongoing SAE or 
AE leading to 
treatment 
discontinuation, 
no week 12 
KCCQ -TSS 
assessment and 
patient alive at 
week 12.-106
3 Patient died before the 
assessment of KCCQ -
TSS at week 12 was 
conducted. Ranked b y time to 
death from 
randomi sationPatient died y  
days after 
randomi sation-108+y /1000
For an y missing week 12 assessment of the CHQ -SAS, the below imputation will be a pplied
for the primary  anal ysis and subgroup anal ysisin accordance to the strategy  for the primary  
endpoint:
Since the lowest possible value for change from baseline in CHQ- SAS dy spnea (fatigue) 
score is [ADDRESS_915019] possible baseline value (7) all imputed values for change from 
baseline are below -6 as described below in Table 6.6.2: 2.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 25of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.6.2: 2Imputation Rules for missing CHQ -SAS Assessments at Week 12
Category Ranking Case description (Imputed) 
Change from 
baseline in 
CHQ -SAS for 
described case 
1 Missing data on CHQ -
SAS at week 12 and no 
clinical event:
Patients with missing 
CHQ -SAS at week [ADDRESS_915020] 
available value of x 
points, no clinical 
event-12 +x/[ADDRESS_915021]-baseline CHQ 
and no clinical 
event -14
2 Missing data and 
clinical event (except 
death).
A clinical event is 
defined as ongoing 
SAE at week 12 or AE 
leading to treatment 
discontinuation and 
patient is alive at week 
12Ranked above 
patients who died, 
but below patients 
with missing data 
and no clinical 
event.Patient has ongoing 
SAE or AE leading 
to treatment 
discontinuation, no 
week 12 CHQ 
assessment and 
patient alive at 
week 12.-16
3 Patient died before the 
assessment of CHQ at 
week 12 was 
conducted. Ranked b y time to 
death from 
randomi sationPatient died y  days 
after randomi sation-18+y /1000
Missing change from baseline due to missing baseline questionnaire will not be imputed.
6.6.3 Secondary endpoints
Handling of missing data for the change from baseline to week 6 in exercise capacity  as 
measured by  [CONTACT_676655] 6 minutes will be analogous to the primary  endpoint, see 
Table 6.6.3:1
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 26of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.6.3: 1 Imputation rules for missing exercise capacity  at week 6
Category Ranking Case description Imputed change 
from baseline 
in 6MWTD for 
described case 
(in m)*
1 Missing data on 6MWT 
at week 6 and no 
clinical event:
Patients with missing 
6MWT at week [ADDRESS_915022] -baseline 
6MWT distance 
and no clinical 
event -354
2 Missing data and
clinical event (except 
death).
A clinical event is 
defined as ongoing 
SAE or AE leading to 
treatment 
discontinuation and 
patient is alive at week 
6Ranked above 
patients who died, 
but below 
patients with 
missing data and 
no clinical event.Patient has 
ongoing SAE or 
AE leading to 
treatment 
discontinuation, 
no information 
of week 6 
6MWT distance 
and patient alive 
at week 6.-
356
3 Patient died before the 
measurement of 6MWT 
at week 6 was 
conducted. Ranked b y time 
to death from 
randomi sationPatient died y 
days after 
randomi sation-358+y /1000
6.6.4 Longitudin al Analyses
There will be different methods of analysingcontinuous longitudinal data. 
Observed case on- treatment (OC -OT):
Only  the available data that were observed while patients were on study  medication (defined 
as time from first drug intake until last permanent treatment stop date plus the endpoint 
specific follow -up time (as defined in Table 6.1 :2)) are considered. 
Measurements are assigned to planned weeks according to Table 6.7: 2
Imputed records are not included
Observed case including data after treatment discontinuation (OC- AD):
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 27of 63
Proprietary confidential information © [ADDRESS_915023] -treatment.
Imputed records are not included.
Measurements are assigned to planned weeks according to Table 6.7: 1 and Table 6.7: [ADDRESS_915024] case imputation (W CI):
All available data as described for OC -AD and additionally  including worst case imputation 
as described in S ections 6.6.1 – 6.6.3. This imputation will only  be considered in non -
parametric anal yses.
6.6.5 Safety Analyses
There will be no imputation of data for safet y analy ses. 
6.6.6 Missing dates
Adverse event data 
Missing or partial date information for AEs will be replaced according to general Boehringer 
Ingelheim (BI) rules described in the BI guidance for handling of missing and incomplete AE 
dates (2).
Partial onset dates from clinical event committee (CEC):
In the unlikel y case that only  the year is documented, the day  and month will be imputed as 
01 Jan unless the subsequently  derived date is before randomisation; in this case the date of 
randomisation will be used as start date. 
If year and month is present the day  will be imputed as first of the month unless the 
subsequently  derived date is before randomisation; in this case the date of randomisation will 
be used.
Death date
For patients with a record of death captured on the electronic case report form (eCRF) with 
missing or only  partial death date from all available sources, the death date will be derived as 
the latest date of an y dates as of: event onset and end dates from either the AE page, or CEC 
adjudicated onset dates, by  [CONTACT_676656] s, range or of possible day s based on 
partial death date and date of last contact . 
Missing information on the date of first administration of trial drug
If the date of first drug administration is missing but the patient was randomised, the date of 
the first drug administration will be set to the date of randomisation. If the date of first 
administration is partially  missing with the month and y ear present, the day will be set to the 
date of randomisation if randomisation was in the same month. If randomi sation was in the 
month prior to the first drug administration the missing day  will be imputed as the first day  of 
the month. 
Missing date of last contact [CONTACT_568]:
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 28of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
If the date is partially  or completely  missing, use the minimum of the following dates:
the date of Informed Consent ( IC)withdrawal (if applicable)
date of death 
If the patient did not die and did not withdraw consent, the latest of: 
ovisit end dates, 
odrug administration dates, 
olast drug stop date, 
olast assessment date (ECG date, date of KCCQ, date of CHQ)  
oAE onset and AE end dates
(in case for partiall y missing date) Last day of the year/month given as partial date
In case of a partially  missing date, if the imputed date is before the first day  of the month/ year 
given as partial date, the first day  of the month/y ear will be used. 
All other cases need to be assessed b y the trial team on an individual patient basis, using the 
above points as guidance.
Missing information on the date of trial medi cation stop
If the date is partially  or completely  missing, use the minimum of the following dates:
End of treatment visit date (if available )
Date of death (if applicable)
Trial completion (last contact [CONTACT_568])
Longest treatment duration (assuming 1 tablet/day )
(in case for partiall y missing date) Last day of the year/month given as partial date
In case of a partially  missing date, if the imputed date is before the first day  of the month/ year 
given as partial date, the first day  of the month/y ear will be used. 
All other cases need to be assessed b y the trial team on an individual basis, using the points 
above as guidance.  
Missing information on concomitant therap y dates
For incomplete date information the midpoint of the possible interval will be used. If onl y the 
year is present the day  and month will be imputed as 01 July , if year and month is present the 
day will be imputed as 15. If the y ear is missing, the date will be considered missing. 
If this leads to contradictions for the start or end date of a concomitant therapy  (e.g. imputed 
end date before documented start date) a partial end date will be imputed as the end of the 
interval or a partial start date will be imputed as the start of the interval in the database to 
resolve this contradiction. 
All other cases or conflicting cases resulting from these imputation rules need to be assess ed 
by [CONTACT_676657].  
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 29of 63
Proprietary confidential information © [ADDRESS_915025] treatment intake.
For randomised patients without any  treatment intake: For serum creatinine and values based 
upon this measurement such as eGFR, baseline will be defined as the mean of all available 
measurements from the screening visit until and including the day  of randomisation. For all 
other endpoints, baseline will be defined as the last available measurement before or on the 
day of randomisation.
Medication taken at baseline is any  medication with start date continued or before date of 
first study  medication intake (randomisation for patients not treated) and end date continued 
or on or after date of first medication intake (randomisation for patients not treated).  
Measurements taken after the first intake of randomised trial medication will be considered 
on-treatment values if they  have been obtained up to end of the parameter spec ific follow - up 
period as defined in Table 6.7: [ADDRESS_915026] -treatment values.
On-treatment (for OC -OT anal ysis) or all post -randomisation (for OC -AD anal ysis) efficacy  
and safet y measurements will be assigned to visits based on time windows around the 
planned visit dates . These time windows are defined based on the planned number of day s 
after the date of first administration of study  drug. 
The time window for the first visit after randomisation starts on the day  after the first intake 
of study  drug. For the primary  anal ysis of the primary  endpoint and the key  secondary  
endpoints, the start of the time window of week 12 assessment will follow the protocol 
defined time window (refer to Table 6.7: 1 for details). For all sensitivity  analy ses and al l 
other endpoints t he midpoint between two on -treatment visits defines the end of a time 
window, with the midpoint being included in the time window of the preceding visit (Table 
6.7: 2 ). 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 30of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.7: 1 Time windows for primary  analysis of primary  and key  secondary  endpoints
and Sensitivity  anal yses using Wilcoxon model
Time window (day s after baseline)
Visit number Visit label Planned day s Start End
2 Baseline11 NA +1
3 Week 6 43 +2 [PHONE_14026] Week 12 85 +78 NA2
1Only values taken prior or on the day of treatment start with randomised study drug can be considered baseline values. To be conservative, 
all data on the day of treatment start will be assumed to be before treatment start for 6MWT and PROs. Time windows will be used for 
assignment of measurements to scheduled visits.
2For patients with no value in the visit 4 window (visit 3 window respectively), determination of imputation categories will be: death s
before day 92 (day 77 respectively) will be considered for imputation category 3 ;value for p atients with clinical event overlappi[INVESTIGATOR_676637] 78 today 92 (day 2 to day 77 respectively )will be imputed according to imputation category 2.
Table 6.7: 2 Time windows for measurement s except primary  analy sis of primary  and key  
secondary  endpoints [OC-OT]
Time window (day s after 
baseline)
Visit number Visit label Planned day s Start End
Endpoints assessed at each on -site visit (e.g. creatinine / eGFR)
2 Baseline11 NA +1
3 Week 6 43 +2 +64
4 Week 12 85 +65 Trt stop + x*
days
FU FU Trt stop + 7 day s Trt stop + x*+ 
1 dayNA
Endpoints that are not assessed on visit 3 (e.g. weight )
2 Baseline11 NA +1
4 Week 12 85 +2 Trt stop+ x*
days
FU FU Trt stop + 7 day s Trt stop + x*+ 
1dayNA
1Only values taken prior to the start of treatment with randomised study drug can be considered baseline values. Time windows will be 
used for assignment of measurements to scheduled visits.
*see Table 6.1: 2
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 31of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.7: 3 Time windows for measurements except primary  analy sis of primary  and key  
secondary  endpoints [OC -AD]
Time window (day s after 
baseline)
Visit number Visit label Planned day s Start End
Endpoints assessed at each on -site visit (e.g. creatinine / eGFR)
2 Baseline11 NA +1
3 Week 6 43 +2 +64
4 Week 12 85 +65 NA
Endpoints that are not assessed on visit 3 (e.g. weight)
2 Baseline11 NA +1
4 Week 12 85 +2 NA
1Only values taken prior to the start of treatment with randomised study drug can be considered baseline values. Time windows will be 
used for assignment of measurements to scheduled visits.
For examinations that are not planned at every  on-treatment visit, the time windows will be 
defined according to the same algorithm, based on the mi dpoint between the planned visit 
day of such an examination. Examples for eGFR and weight can be found in Table 6.7: 
2for 
OC-OT anal yses and in Table 6.7: 3 for OC -AD anal yses.
Only  one observation per t ime window will be selected for anal ysis at an on- treatment visit –
the value will be selected which is closest to the protocol planned visit day . 
For the primary  endpoint (6MWTD) and an y measurement related to the 6MWT assessment
the longest walking distance for each day will be used for the analysisfor that day .
If there are two measurement swhich have the same time difference in day s to the planned 
day,or if there are two measurements on the same day (endpoints not related to the 6MWT ), 
the first value will be used.
Baseline definition for concomitant therapi[INVESTIGATOR_676638] m edication taken at baseline is an y medication with start date continued or 
before date of first study  medication intake (randomisation date will be used for patients not 
treate d) and end date continued on or after date of first study  medication intake 
(randomisation date will be used for patients not treated). 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 32of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7. PLANNED ANALYSIS
For End -Of-Text (EoT) tables, the set of summary statistics is: N / Mean / standard deviation 
(SD) / standard error (SE) / Min / lower quartile ( Q1)/ Median / upper quartile (Q3)/ Max. 
The 1st and 99th percentiles might be substituting minimum and maximum in tables with 
open -ended values to safeguard against implausible extremes. Final decision will be made at 
the final BRPM.
Geometric means and gCV will be added to the presentation or replace the presentation of 
mean, standard error and standard deviation for parameters (e.g. NT-proBNP) that follow a 
log-normal distribution rather than a normal distribution. 
Statistical parameters will be display ed to a defined number of decimal places as specified in 
the BI guideline “ Standards for Reporting of Clinical Trials and Project Summaries” ( 3)
Tabulations of frequencies for categorical data will include all possible categories and will 
display  the number of observations in a category  as well as the percentage (%) relative to the 
respective treatment group (unless otherwise specified, all patients in the respec tive patient 
set whether they  have non -missing values or not). Percentages will be rounded to one decimal 
place. The category  missing will be display ed onl y if there are actuall y missing values.
Disposition of the patient population participating in the trial will be analysed by [CONTACT_676658] a frequency distribution. The number of 
patients participating (screened, randomi s
ed, screened but not randomis ed, etc.) in the study  
by [CONTACT_11338], country  and, for treate d patients, centre, will also be analysedby [CONTACT_676659] a frequency  distribution. 
Disposition as required for reporting for the trial in EudraCT will be provided. Enrolment 
will be summari sed by  [CONTACT_676660] . 
The reasons for not randomi sing screened patients will be summari sed descriptively. 
The frequency  of patients with iPDs will be presented by [CONTACT_676661]. The frequency  of patients in different anal ysis sets will also be anal ysed for each 
treatment group.
7.1 D EMOGRAPHIC AND OTHER BASELINE CHARACTERIS TICS
Only  descriptive statistics are planned for this section of the report.
Demographics and baseline characteristics will be anal ysed based on RS. Demographics wil l 
be repeated on the TS if the number of patients in the analysis sets differ b y more than 5%.
Standard descriptive analy sis and summary  tables will be presented. These summary  tables 
will include description of variables detailed in Section 6.4 .In addition, d escriptive anal yses 
of the following continuous variables measured at baseline will be presented: Age, bod y mass 
index (BMI), time since HF-diagnosis, s ystolic blood pressure (SBP), diastolic blood pressure 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 33of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
(DBP), weight, eGFR, NT-proBNP , heart rate . For patients with diabetes at baseline, HbA 1c
at baseline will be shown descriptivel y.
7.2 C ONCOMITANT DISEASES AND MEDICATION
Only  descriptive statistics are planned for this section of the report using the randomised set. 
Concom itant medication use will be summarised by  [CONTACT_243653]- Therapeutic -Chemical 
classification level 3 (ATC1 -ATC2- ATC3) and preferred name. Summaries will be presented 
for concomitant therapi[INVESTIGATOR_676639] y those added after baseline .
Separa te summaries of use of heart failure
-related drugs (e.g. ARNi, beta- blockers, 
ivabradine, diuretics, ACE -inhibitors, ARBs, MRAs , cardiac gl ycosides ), anticoagulants, 
acetylsalicy lic acid (ASA), or lipid lowering drugs at baseline and separately  those for added 
after baseline will be presented. Definitions of these medication groups are based on World 
Health Organization Drug Dictionary  (WHO DD) a nd are stored in the Project Data 
Management and Anal ysis Plan (PDMAP).
Use of devices at baseline will also be summarised.
Concomitant diseases will be summarised by  [CONTACT_6657]. Relevant 
medical history  by [CONTACT_528366]. Both summaries will be presented 
using the randomised set.
The number and percentage of patie nts receiving the best tolerated treatment for HF 
symptoms and other common concomitant diseases or sy mptoms (e.g. hy pertension, diabetes, 
cardiac arrh ythmia, fluid retention) according to prevailing guidelines in the opi[INVESTIGATOR_676640].
7.3 T REATMENT COMPLIANCE
Only  descriptive statistics are planned for this section of the report. The number and 
percentage of patients with overall study  medication compliance will be reported. 
7.4 P RIMARY ENDPOINT
7.4.1 Primary analysis of the pr imary endpoint
The primary  endpoint ‘change from baseline to week 12 in exercise capacity ’ as measured by  
[CONTACT_558873] [ADDRESS_915027], non -parametric Hodges -Lehmann estimate for the median difference 
will be used. Corresponding 95% confidence intervals will be display ed. Any confirmatory  
conclusion such as for hierarchical testing will be based on the result of the Wilcoxon rank 
test and will not consider the Hodges -Lehmann estimate or the corresponding confidence 
interval, which are given to support interpretation.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 34of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
If no 6MWTD is available at week 12, an imputed value as defined in Section 7.5 of the CTP 
will be used. 
The primary  anal ysis will be conducted on all randomi sed patients , regardless of whether on 
or off -treatment on the day  of 6MWT assessment . Where more than one measurement is 
available for the same day  (duplicate measurements), the longest distance walked will be 
used for analy sis.In case more than one 6MWT result sin the same distance walked, the first 
assessment will be used for anal ysis.
7.4.2 Sensitivity analysis of the primary endpoint
Sensitivity  analy sis for the primary  endpoint will include ;
a mixed model repeated measure anal ysis (MMRM) without imputation of missing 
values (OC-AD).
anMMRM restricted to on- treatment values (OC-OT).
The model will include visit -by-treatment intera ction and baseline -by-visit interaction. An 
unstructured covariance structure will be used to model the within -patient errors. Descriptive 
statistics will be calculated for the value at visit and change from baseline based on OC -AD 
on the randomised set an d based on OC -OT on the treated set. The MMRM analy ses will also 
be shown graphically .
The primary  anal ysis will be repeated restricted to patient in the sensitivity  anal ysis set
SensRS1 , SensRS2 and SensRS3.
If the mean difference between the treatment groups in 6MWTD is above 15m at baseline,
the primary  analy sis will be repeated, but using the ranks of the residuals from the following 
linear regression model
6MW TD 12weeks ~6MWTD Baseline
with patients without week 12 data ranked below any patient with wee k 12 assessment 
similar to the rules for primary  anal ysis.
7.4.3 Subgroup analysis of the primary endpoint
The primary  anal ysis of the primary  endpoint will be repeated for each subgroup as defined 
in Table 6.4: 1. A forest plot s ummarising all subgroup anal yses will be shown. 
7.[ADDRESS_915028] in the next step. In the next step a 
Hochberg procedure will be applied to account for multiplicity of testing of the key secondary 
endpoints:
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 35of 63
Proprietary confidential information © [ADDRESS_915029] p -value of the primary  anal ysis of the two key  secondary  endpoints is below 
5%, both null hy pothese s of the key  secondary  endpoints will be rejected. Otherwise, if the 
smaller p- value of the primary  anal ysis of the two key  secondary  endpoint s is below 2.5%, 
only the corresponding null hy pothesis can be rejected. 
If the primary  hypothesis of the primary  endpoint is not rejected, the tests of the key  
secondary  endpoints are conducted in an exploratory  manner .
[IP_ADDRESS] Primary  anal ysisof the 
key secondary  endpoints
The two key secondary endpoints ‘ Change from baseline to week 12 in KCCQ -TSS’ and 
‘Change from baseline to week 12 in CHQ -SAS dyspnea score’ are part of the testing 
strategy. 
Both key secondary endpoints ‘Change from baseline to week 12 in heart failure symptoms as 
measured by [CONTACT_676662]’ and ‘ Change from baseline to week 12 in CHQ- SAS dyspnea 
score’ will be evaluated using a normal approximation of the Wilcoxon rank test using the 
randomi sed set. For estimation of effect the non- parametric Hodges -Lehmann estimate for 
the median difference will be calculated.
Change from baseline in both scores will be defined as the endpoint value at week [ADDRESS_915030] available endpoint value before start of randomised trial medication.
If no questionnaire is available at week 12, an imputed value as defined in Section 6.6 will be 
used. 
[IP_ADDRESS] Sensitivity  analy sisof the key  secondary  endpoints
Sensitivity  analy sis for the key  secondary  endpoint will include 
a mixed model repeated measure anal ysis without imputation of missing values (OC-
AD).
a mixed model repeated measure anal ysis restricted to on treatment values (OC-OT).
The model will include visit -by-treatment interaction and baseline- by-visit interaction. An 
unstructured covariance structure will be used to model the within -patient errors. Descriptive 
statistics will be calculated for the value at visit and change from baseline based on OC -AD 
on the randomised set and based on OC -OT on th e treated set .
The primary  anal ysis will be repeated restricted to patients in sensitivity  analy sis sets 
SensRS2 and SensRS3.
7.5.1. 3Subgroup anal ysisof the key  secondary  endpoints
The primary  anal ysis of the key  secondary  endpoints will be repeated for each subgroup as 
defined in Table 6.4: 1. A forest plot summarising all subgroup anal yses will be shown. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 36of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
[IP_ADDRESS] Further exploratory analyse sof the key  secondary  endpoints
A minimal clinically  meaningful within-patient change in scores (i.e. responder threshold) 
will be estimated from the trial population (both treatment groups pooled) for KCCQ -TSS 
and CHQ -SAS dy spnea as described in Appendix 9.3.
Aresponder anal ysis using a chi -square test will be evaluated in addition. The response 
threshold will be determined as defined in Appendix 9.3. 
Anempi[INVESTIGATOR_676641] 12 
by [CONTACT_676663] -AD on the randomised set will be shown.
7.5.2 Other Secondary endpoints
Other secondary endpoints will not be part of the testing hierarchy. No correction for 
multiple testing of the other secondary  endpoints will be made.
Change from baseline to week 6 in exercise capacity as measured by [CONTACT_676655] 6 
minutes will be evaluated using the same model as for the primary endpoint. If no 6MWTD is 
available at week 6, an imputed value as defined in Section 6.6 will be used. 
All other secondary endpoints will take into account all data, regardless of whether the 
patient was on treatment or not, and without imputation of missing values (OC-AD).
The other continuous endpoints are generally  analysed in anMMRM, including visit-by-
treatment interaction and baseline -by-visit interaction. An unstructured covariance structure 
will be used to model the within -patient errors. The MMRM analy ses will also be shown 
graphicall y.
Descriptive statistics will be calculated for the value at visit and change from baseline.
Shift from baseline score to 12 week score will be tabulated descriptively  for single items 
collected in the context of the clinical congestion score (d yspnea, orthopnea, fatigue, jugular 
venous distension, rales and edema).
The endpoint “Change from baseline in NT -proBNP at week 12” (after log -transformation) 
will be evaluated using a nMMRM analy sis over time with baseline log -transformed NT -
proBNP b y visit int eraction and visit by  [CONTACT_676664]. Estimates obtained from the model will then be back -
transformed and reported on the original scale. The MMRM analy ses will also be shown 
graphicall y.
Proportion of patients in every  category  of global impression of change at week [ADDRESS_915031] on the difference in mean treatment scores, 
using modified ridit scores.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 37of 63
Proprietary confidential information © [ADDRESS_915032] on the difference in mean treatment scores, using modified ridit scores.
Difference in score will be defined as the number of categories improved/deteriorated from 
baseline. Shift from baseline score to 12 week score will be tabulated descriptively .
7.6 F URTHER ENDPOINT S
All further endpoints will take into account all data, regardless of whether the patient was on 
treatment or not , and without imputation of missing values (OC-AD).
7.6.[ADDRESS_915033] to compare response between treatment groups.
•Increase in 6MWT ≥ 30 m from baseline at week 12
•Response in KCCQ domains at week [ADDRESS_915034] plot of 
response at week 12 for each domain by  [CONTACT_676665]. 
•Response in CHQ domains at week [ADDRESS_915035] plot of response 
at week 12 for each domain by  [CONTACT_676665]. 
Descriptive statistics are planned for all other binary  endpoints:
•Occurrence of HHF and Cardiovascular ( CV)death
•Occurrence of all -cause mortality
•Occurrence of CV death
•Occurrence of all -cause hospi[INVESTIGATOR_73256] (first and recurrent)
•Occurrence of hospi[INVESTIGATOR_676642] (first and recurrent)
•Occurrence of all -cause emergency  room visits (first and recurrent)
•Emergency  room visit for HF (requires use of i.v. diuretics; first and recurrent)
•Occurrence of unscheduled outpatient visit (first and recurrent)
•Intensification of diuretic therapy  (adding a new diuretic, increase of dose)
•Occurrence of MI (fatal or non -fatal)
•Occurrence of Stroke (fatal or non -fatal)
•Occurrence of TIA
7.6.2 Ordinal endpoints
The following endpoints will be evaluated using the same models as defined for the 
corresponding secondary  endpoints:
•Change from baseline in Patient Global Impression of Severity  of Heart Failure 
Symptoms at week 6.
•Change from baseline in Patient Global Impress ion of Severity  of Dy spnea at week 6.
•Patient Global Impression of Change in Heart Failure Sy mptoms at week 6.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 38of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
•Patient Global Impression of Change in Dy spnea at week 6.
•Change from baseline in Clinician Global Impression of Severity  of Chronic Heart Failure 
(CHF )at Week 6 and week 12
•Clinician Global Impression of Change in CHF Severity  at Week 6 and week 12
Frequencies and proportions of patients categori sed descriptiv ely by [CONTACT_941] 
shift in NYHA class from baseline to week 6 and to week 12.
7.6.3 Continuous endpoints
Further continuous endpoints are generall y analy sed in a mixed model with repeated 
measures (MMRM), including visit -by-treatment interaction and baseline -by-visit interaction. 
An unstructured covariance structure will be used to model the within- patient errors. The 
MMRM analy ses will also be shown graphically .
Descriptive statistics will be calculated for the value at visit and change from baseline . 
•Change from baseline in KCCQ overall summary  score, CSS, and individual domains at 
Week 6 and week 12
•Change from baseline in CHQ individual domains at week 6 and week 12
•Change from baseline in SBP at Week 6 and week 12
•Change from baseline in DBP at Week 6 and w eek 12
The following endpoint is assessed as part of the main analy sisor sensitivity  analy sisof the 
corresponding secondary  endpoint:
•Change from baseline in KCCQ TSS at Week 6
•Change from baseline in CHQ -SAS dy spnea at Week 6
•Change from baseline in Cl inical Congestion Score at week 6.
•Change from baseline in NT -proBNP at week 6.
Since body weight is only measured at baseline and week 12, an ANCOVA model will be 
presented including baseline weight as a covariate. 
Descriptive statistics areplanned for:
•Change from baseline to week [ADDRESS_915036] value on treatment and follow -up will be presented for patients with 
valid measurements at all three time points
. . 
SBP
DBP
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 39of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.7 E XTENT OF EXPOSURE
Descriptive statistics tables based on the TSwith mean, SD, SE, quartiles, median and range 
of the number of day s a patient was on treatment will be provided. These tables will also 
provide the sum -total of the time (in y ears) that all patients were on treatment.
Frequency  tables of number and percentage of patients belonging to categorical ranges of 
exposure weeks will be provided as well. Following are the categories of exposure -ranges (in 
weeks): >= 0 weeks, >= 4weeks, > = 8weeks, >= 11 weeks .
7.8 S AFETY ANALYSIS
The safet y analysis will be based on the treated set (TS). 
Whil e tables will generally display results b y randomised treatment, listings will reflect 
whether a measurement/AE occurred on or off treatment.
7.8.1 Adverse events
Unless otherwise specified, the anal yses of adverse events (AEs) will be descriptive in natur e 
and will be based on the number of patients with AEs and not on the number of AEs.
AEs will be coded using version 22.0 of the Medical Dictionary  for Regulatory  Activities 
(MedDRA) coding dictionary . 
Definitions of Boehringer Ingelheim customi
sed MedDRA Queries (BIcMQs) for new 
MedDRA versions are maintained b y the BI dictionary maintenance group. 
For analy sis multiple AE occurrence data in the data from the eCRF will be collapsed into an 
AE provided that all of the following applies:
•All AE attributes are identical (including Lowest Level Term ( LLT), intensity , action 
taken, therap y required, seriousness, reason for seriousness, relationship, outcome, AE of 
special interest and also additional information of specific AEs or AESIs such anatomical 
location of UTI (upper UTI  kidney  versus Lower UTI bladder and below versus 
asymptomatic bacteriuria) or type of genital infection (fungal balanitis or vulvovaginitis 
versus other than fungal balinitis or vulvovaginitis)).
•The occurrences were time -overlappi[INVESTIGATOR_676643] e-adjacent (time -adjacency  of [ADDRESS_915037] occurrence).
For further details on summaris ation of AE data, please refer to (2).
[IP_ADDRESS] Assignment of AEs to treatment
The anal ysis of adverse events will be based on the concept of treatment -emergent adverse 
events. That means that all adverse events occurring between first drug intake till [ADDRESS_915038] drug int ake will be assigned to the randomised treatment. All adverse events occurring 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 40of 63
Proprietary confidential information © [ADDRESS_915039] drug intake will be assigned to ‘pre -treatment’ and all adverse events occurring 
after last drug intake + 7 day s with be assigned to ‘follow -up’, except if otherwise specified.
InSection 15.3 general AE anal ysis tables will present onl y on-treatment AEs (appl ying the 
rule of 7 day s for assignment as on -treatment) for the treatments groups. 
Appendix 1 [IP_ADDRESS] will include an analy sis (overall summary table, frequency  of AEs by  
[CONTACT_9313] (SOC) / preferred term (PT), frequency  of serious adverse events (SAEs) 
by [CONTACT_2946]/PT) where AEs and SAEs are assigned to the following phases: Screening, each 
treatment g roup, post -treatment for each treatment group.
For listings, AEs will be assigned to one of the treatment phases of Screening, Placebo, Empa 
10, Post P lacebo, Post Empa. 
[IP_ADDRESS] AE summaries
An overall summary  of adverse events will be presented. 
The frequency  of patients with adverse events will be summarised by  [CONTACT_3148], primary  
sys
tem organ class and preferred term. Incidence rates as defined in Section [IP_ADDRESS] will 
generall y be included. 
AEs will also be reported by  [CONTACT_2236]  (without incidence rates). Separate tables will be 
provided for 
for patients with serious adverse events, 
for patients with drug related serious AEs,
for patients with AEs leading to discontinuation
for patients with drug -related AEs .
AEs leading to death will be listed. 
The sy stem organ classes will be sorted according to the standard sort order specified by  [CONTACT_50743]  (EMA), preferred terms will be sorted by  [CONTACT_35043]  (within 
system organ class).
Additionally , the following anal yses will be reported in Appendix 16.1. 13.[ADDRESS_915040] and clinicaltrials.gov:
Frequency  [N(%)] of subjects with non -serious adverse events occurring with 
incidence in preferred term greater than 5% b y treatment,
Adverse events per arm for disclosure on EudraCT by  [CONTACT_3148]
Non-serious adverse e vents for disclosure on EudraCT by [CONTACT_3148]
Serious a dverse events fo r disclosure on EudraCT by [CONTACT_676666]: 1245-0168 Page 41of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
[IP_ADDRESS] Adverse events of special interest (AESIs) 
Hepatic injury
Hepatic injury  AEs will be summari sed based on a Standardised MedDRA Query  (SMQ )
based definition. From SMQ Drug related hepatic disorders (20000006) the following narrow 
sub-SMQs will be used:
Narrow sub -SMQ L iver related investigations, signs and sy mptoms (20000008)
Narrow sub-SMQ Cholestasis and jaundice of hepatic origin (20000009)
Narrow sub -SMQ Hepatitis, non- infectious (20000010)
Narrow sub -SMQ Hepatic failure, fibrosis and cirrhosis and other liver damage -
related conditions (20000013)
A table with frequencies of patie nts with these AEs by  [CONTACT_3148], primary  SOC and preferred 
term will be provided. Hepatic injury SAEs based on the above SMQ definition will be 
presented. 
Patients with hepatic injury  will be listed.
For presentations on adjudicated hepatic events, refer to Section [IP_ADDRESS].
Acute renal failure
A frequency  table of patients with AEs related to acute renal failure by [CONTACT_3148], primary  
SOC and preferred term will be provided based on the narrow SMQ Acute renal failure 
(20000003) . 
SAEs and AEs leading to discontinuation based on the narrow SMQ Acute renal failure 
(20000003) will be presented. 
In addition, frequency  tables will be produced for patients with elevated creatinine ≥ 2 x 
baseline and > 1 xupper limit of normal (UL N).
Patients with acute renal failure will be listed.
Ketoacidosis
A frequency  table of patients with AEs related to ketoacidosis will be presented b y treatment, 
primary  SOC and preferred term for investigator reported cases and for the narrow and broad 
BIcMQ definition of diabetic ketoacidosis (DKA) .
For presentations on adjudicated events, refer to Section 7.8.1. [ADDRESS_915041] BIcMQ (30000019) or investigator reported 
ketoacidosis will be listed. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 42of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
[IP_ADDRESS] Spec ific AEs
Hypoglycaemic events
The investigator will record for each AE whether it represents a h ypogl ycaemic event and, if 
so, record additional information to assess the intensity  of the hy poglycaemic event. On the 
basis of this information the hy poglycaemic event will be categorised as follows:
severe h ypogl ycaemic epi[INVESTIGATOR_1865]: event requiring the assistance of another person to 
activel y administer carbohydrate, glucagon or other resuscitative actions
documented s ymptomatic hy poglycaemia with a measured plasm a glucose 
concentration < 3.0 mmol/L  (< 54 mg/dL): event accompanied b y typi[INVESTIGATOR_676644]
documented s ymptomatic hy poglycaemia with a measured plasma glucose 
concentration ≥ 3.0 mmol/L  and ≤ 3.9 mmol/L  (≥54 mg/dL and ≤ 70 mg/dL): event 
accompanied b y typi [INVESTIGATOR_676645]
symptomatic hy pogly caemia and plasma glucose concentration > 3.9 mmol/L  (70 
mg/dL)
symptomatic hy pogly caemia and plasma glucose concentration not m easured
asymptomatic hy poglycaemia: event not accompanied by  [CONTACT_11017][INVESTIGATOR_330922] a measured plasma glucose concentration ≤ 3.9 mmol/L  (≤ 
70 mg/dL)
Confirmed hy poglycaemic adverse event are defined as hy poglycaemic adverse events tha t 
hada plasma glucose concentration ≤ 70 mg/dL  or required assistance.
Different tables will be shown for (i) patients with investigator -defined hy poglycaemia, and 
(ii) patients with confirmed hy poglycaemic adverse events, i.e. h ypogl ycaemic adverse 
events that had a plasma glucose concentration ≤ 70 mg/dL or required assistance.
Subgroup anal yses on confirmed events with respect to DM status at baseline (DM vs non-
DM) will be performed.
In addition the number of patients with hy poglycaemia according to SMQ (20000226) will be 
presented.
Patients with hy poglycaemic events will be listed. 
Urinary  tract infections ( UTI)and genital infections
The following additional specific adverse events will also be assessed and be tabulated b y 
treatment group:
Genit al infections (BIcMQ “Infections” (30000036) narrow subsearch 1.1 “ Genital 
tract infections predisposed to by  [CONTACT_547897] ” (30000038) and investigator 
assessment)
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 43of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
UTI (BIcMQ “Infections” (30000036) narrow subsearch 2.1 “ UTI predisposed by  
[CONTACT_547897] ” (30000041) and investigator assessment)
Genital infections based on investigator assessment will additionally  be summarised by  [CONTACT_24975] 
(fungal balanitis or fungal vulvovaginitis, genital infection other than fungal balanitis or 
fungal vulvovaginits), intensity (mild, moderate or severe), how the event was treated (no 
treatment, therap y assigned and n umber of antimicrobials needed to treat ), whether leading to 
discontinuation of treatment, and the number of epi[INVESTIGATOR_302054]. 
UTIs based on investigator asse ssment will additionally  be summarised by [CONTACT_2236]  (mild, 
moderate or severe), anatomical location (upper UTI , lower UTI), occurrence of 
pyelonephritis or urosepsis, how the event was treated (no treatment, therapy  assigned and 
number of antimicrobials ne eded to treat ), whether leading to discontinuation of treatment, 
and the number of epi[INVESTIGATOR_302054]. 
Complicated urinary  tract infections defined as serious adverse events of BIcMQ Infection 
narrow ,subsearch 2.1 “UTI predisposed by  [CONTACT_547897] ” (30000041) , all events of sub search 
2.1.1 ‘Renal infections predisposed by  [CONTACT_547897]’ (30000042), all events of PT Urosepsis 
will be presented. 
Complicated genital infection: defined as all serious events using the BIcMQ Infection 
narrow subsearch 1.1 ‘Genital tract infections predisposed to by  [CONTACT_547897] ’(30000038) and 
all event of the subsear ch ‘Complicated genital tract infections predisposed to by  [CONTACT_547897]’ 
(30000129) will also be presented. 
Patients with UTIs or genital infections will be listed. 
Bone fracture events:
Frequency  tables of patients with bone fracture by [CONTACT_3148], primary  system organ class 
(SOC) and preferred term will be provided (based on the narrow BIcMQ “Bone fractures”
(30000008) and investigator reporting). 
Investigator repor ted fractures will be reported overall and separatel y for each type of 
fracture (traumatic andnon-traumatic).
Separate tables for bone fractures based on the BIcMQ, which are serious will be presented. 
Patients with bone fractures will be listed.
Urinary  tract malignancy events:
Urinary  tract malignancy will be shown based on the BIcMQ ‘Malignancies’ (30000049) –
broad sub -search 14.1 ‘ Urinary  bladder and tract malignancies
’(30000057) andbroad sub -
search 14.2 ‘Renal malignancies’ (30000103) :
Presentation of frequency will be done by [CONTACT_3148], high level term and preferred term .
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 44of 63
Proprietary confidential information © [ADDRESS_915042] malignancy will be listed. 
Volume depletion
Volume depletion will be based on the BIcMQ ‘ Volume depletion of non -haemorrhagic 
cause and su bsequent hypotension ’–narrow subsearch 2 ‘V olume depletion and hy potension 
due to deh ydration ’(30000090) . 
A frequency  table of patients with volume depletion by  [CONTACT_3148], primary  SOC and preferred 
term will be provided. 
A separate table for serious volume depletion events will be presented. 
Patients with volume depletion will be listed.
For the anal ysis of laboratory  data, refer to Section 7.8.2 .
Hypotension:
Frequency  table of subjects with sy mptomatic hypotension as defined by [CONTACT_676667], primary  system organ class and preferred term will be 
provided.
Symptomatic hy potension epi[INVESTIGATOR_676646]-diuretic antihy pertensive therapy  
was reduced. 
A separate table for symptomatic hy potension events, which are serious ,will be presented. 
Additionally  hypotension by
 [CONTACT_3148], primary  system organ class and preferred term will be 
provided. Hypotension is defined as preferred terms of the BIcMQ ‘Volume depletion of non -
haemorrhagic cause and subsequent hy potension’ –narrow sub -search 2 ‘Volume depletion 
and hy potension due to dehy dration’ (30000090) but excluding terms of the narrow subsearch 
1 ‘Volume depletion due to dehy dration’(30000089).
A separate table for h ypotension events, which are serious, will be presented. 
Patients with hy potension events will be listed.
[IP_ADDRESS] Events qualify ing for external adjudication by  [CONTACT_676668] -
specified 
criteria for these adjudication endpoints are met. Details on composition of the CEC, 
responsibilities and clinical event definitions are provided in the separate CEC Charter. 
Adjudication assessments will be incorporated into the database. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 45of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Details of the adjudication process are described in the CEC charter.
Hepatic adverse events:
Frequency  tables summari sing the relatedness and severit y will be provided, including a 
listing showing the trigger events and adjudication results. This will include all adjudicated 
events up t o 30 day s after treatment stop.
Ketoacidosis:
Frequency  tables showing adjudicated cert ain ketoacidosis will be provided, including a 
listing showing the trigger events and adjudication results. This will include all adjudicated 
events up to 7 day s after treatment stop. 
[IP_ADDRESS] AEs while patients taking wrong medication
A listing will be provided f or AEs that occurred while a patient was taking the wrong study  
medication.  
If such a patient is identified a n additional adverse event table that assigns the adverse events 
to the actual treatment taken will be presented. A patient who took both the ass igned 
treatment and also at least one tablet of the wrong treatment will be counted as at risk in both 
treatment groups for the respective relevant time. The table will include all adverse events by  
[CONTACT_3592]. 
[IP_ADDRESS] Adverse event incidence rates
For AE tables showing patients with events, i n addition to the frequency  tabulations, time -
adjusted adverse event analy ses will be performed for all AEs, investigator defined drug -
related AEs, AEs leading to discontinuation, serious AEs, and adverse events of special 
interest by  [CONTACT_676669] -Level Term ( HLT )and PT, respectivel y.
The time at risk in patient y ears for the on-treatment phase is derived as follows:
Patients with AE: 
time at risk (AE) in day
s = date of start of AE with specified PT/SOC/HL T –study  treatment 
start date + 1 
Patients without AE: 
time at risk (AE) in day s = end date of time at risk – study  treatment start date + 1, where end 
date of time at risk is the minimum of date of last study  drug intake + x days and date of 
death, if applicable.
The standard approach will be x=7 day s, but for certain AESIs in addition other approaches 
will be used.
Total AE -specific time at risk per treatment group is then derived as: 
Time at risk (AE) [y ears] = Sum of time at risk [day s] over all patients in a treatment group/ 
365.25
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 46of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
For ‘each row of a table’ (e.g. display ing an SOC), time at risk is calculated using start of 
first AE summari sed in this row; e.g. for patient with AE in a specified SOC, time at risk = 
date of start of AE with specified PT in this SOC –start of study  treatment + 1.
The AE incidence rate per 100 patient y ears will then be calculated as follows:
Incidence rate per 100 patient y ears (pt -yrs) = 100 * number of patients with AE / time at risk 
(AE) [y ears].
In a similar way  the tim e at risk and incidence rate for the post -treatment period is derived. 
Hereb y the start date is the start date of the post -treatment phase instead of the study  
treatment start date.
For some specific outputs showing number of epi[INVESTIGATOR_1841], event rates will be defined as number 
of epi[INVESTIGATOR_676647]. Time at risk will be end date of time at risk –study  
treatment start date + 1, where end date of time at risk is the minimum of date of last study  
drug intake + x day s and date of death, if applicable .
7.8.[ADDRESS_915043] analy ses for safet y 
laboratory  data are described in the BI guidance for the Display  and Analy sis of Laboratory  
Data (BI-KMED -BDS -HTG -0042 (4)).All anal yses considering multip le of times upper limit 
of normal (ULN) will be based on original and not normalis ed data.
Laboratory  parameters will be shown in conventional units. Where conventional units differ 
from SI units, analy ses will be repeated on SI units. 
The anal yses of laboratory  data will be descriptive in nature and will be based on BI 
standards [see Data Management and Statistics Manual (DM&SM): Display  and Anal ysis of 
Laboratory  Data (BI-KMED -BDS -HTG - 0042 (4)) ].
Laboratory  measurements taken up to [ADDRESS_915044] administration of randomised study  
drug will be considered as on- treatment.
Default settings will be used for repeated values (using closest and then worst value).
Laboratory  values will be compared to their refer ence ranges and frequency tables will be 
provided for the number of patients within and outside the reference range at baseline and the 
last measurement on treatment.  Descriptive statistics will be provided b y treatment group for 
baseline, last value on -treatment and for changes from baseline to last value on treatment.  
For semi -quantitative or categorical laboratory  values, shift tables for baseline and last value 
on treatment will also be provided. Frequency  tables will summarise the number of patients 
with potentially  clinically  significant abnormalities. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 47of 63
Proprietary confidential information © [ADDRESS_915045] on available on- treatment value. All individual data 
will be presented in listings. 
To support anal yses of liver -related adverse drug effects, patients with Aspartate 
transaminase (AST) and/or Alanine transaminase (ALT) ≥3xUL N with concomitant or 
subsequent Total Bilirubin (TBILI ≥2xU LN) in a [ADDRESS_915046]/ALT elevation are 
of special interest. In addition, of these cases, it will be considered whether the alkaline 
phosphatase (AP) is less than 2 x UL N (maximum value in a [ADDRESS_915047]/ALT 
elevation) or not. The start of the 30 -day time span is triggered by  [CONTACT_676670]. Patients who fulfil one or two of the criteria for 
ALT/AST or total bilirubin elevations above and have no information available for the 
remaining par ameter(s) within the 30 day  time window will not be listed under “ALT and/or 
AST ≥ 3xUL N with TBILI ≥ 2xULN”. 
In addition AL T/AST will be used to investigate elevated liver enz ymes:
ALT/AST ≥ [ADDRESS_915048]
ALT/AST ≥ [ADDRESS_915049]
ALT/AST ≥ [ADDRESS_915050]
ALT/AST ≥ [ADDRESS_915051]
All liver enzy me elevations within 30 day s of treatment discontinuation will be shown.
Frequency  tables of patients with elevated liver enzy mes defined by  [CONTACT_676671]/or AST, total 
bilirubin and AP combinations will be provided.  Details on patients with elevated liver 
enzy mes will be listed.
For the following parameters:
eGFR,
creatinine (only  descriptive),
the time course of changes will be assessed. The analy sis will be performed by  [CONTACT_676672] -OT data on the treated set. The MMRM models that will be used are 
specified in Section 7.6. These analy ses will be conducted on data before any  normali sation.
The MMRM anal yses will also be shown graphically . 
For the following parameters:
haemoglobin, and 
haematocrit 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 48of 63
Proprietary confidential information © [ADDRESS_915052] ying 
ANCOVA models to OC -OT data on the treated set. The ANCOVA model will include 
treatment and baseline as fixed effects. Theses analy ses will be conducted on data before an y 
normali sation.
To support anal ysis of renal function, eGFR throughout the trial will be categori sed according 
to the following Chronic Kidney  Disease (CKD )staging (Table 7.8.2: 1 ): All calculations for 
the staging of renal function wi ll be based on the originall y measured laboratory  values, not 
on normalised values with BI standard reference ranges. 
For the following parameters measure dat the follow -up visit, additionally  descriptive 
statistics at baseline, last value on treatment and follow-up will be provided for patients with 
valid measurements at all three time point s. 
creatinine
eGFR
haematocrit
haemoglobin
Table 7.
8.2: 1 CKD stag ing
Stage eGFR 
(mL/min /1.73m ²)Description Label for 
displaysAdditional labels#
1 ≥90 Normal or high ≥90 ≥90 (CKD 1)
2 60 to <90 Mildly  decreased 60 to <90 60 to <90 (CKD 2)
3A 45 to <60 Mildly  to 
moderatel y 
decreased45 to <60 45 to <60 (CKD 3a)
3B 30 to <45 Moderatel y to 
severel y decreased30 to <45 30 to <45 (CKD 3b)
4 15 to <30 Severel y decreased 15 to <30 15 to <30 (CKD 4)
5 <15 Kidney  failure <15 <15 (CKD 5)
A shift table from baseline to last value on treatment and to minimum value on treatment for 
eGFR (CKD -EPI) crwill be provided.
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 49of 63
Proprietary confidential information © [ADDRESS_915053] appeared after signing of consent.
Outcomes of ECG s will be part of the reporting of medical history  or AE reporting. 
Categorical findings as collected in the eCRF will al so be summari sed descriptively .
7.8.5 Others
Not applicable
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 50of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
8. REFERENCES
1CPMP/ICH/363/96: "Statistical Principles for Clinical Trials", ICH Guideline Topic 
E9, Note For Guidance on Statistical Principles for Clinical Trials, current version.
2BI-KMED -BDS-HTG -0035 :"Handling of missing and incomplete AE dates", current 
version; IDEA for CON.
3BI-KMED -BDS-HTG -0045 : "Standards for Reporting of Clinical Trials and Project 
Summaries", current version; I DEA for CON.
4BI-KMED -BDS-HTG -0042 : "Handling, Display  and Analy sis of Laboratory  Data", 
current version; IDEA for CON.
5Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG . Clinically  meaningful change 
estimates for the six -minute walk test and daily activity  in individuals with chronic 
heart failure. Cardiopulm Phy s Ther J 24 (3), 21 
-29 (2013) [R17 -1227]
6Crosby  [CONTACT_135569], Kolotkin RL, Williams GR . Defining clinically meaningful change in 
health
-related quality  of life. J Clin Epi[INVESTIGATOR_5541] 56, 395 - 407 (2003) [R07-1182]
[ADDRESS_915054], Spertus JA. Development and evaluation of the 
Kansas City  Cardiomy opathy  Questionnaire: a new health status measure for heart 
failure. J Am Coll Cardiol 35 (5), 1245 -1255 (2000) [R17-2666]
8Bennett SJ, Oldridge NB, Eckert GJ, Embree J L, Browning S, Hou N, et al . 
Comparison ofquality oflifemeasures inheart failure. Nurs Res 52 (4), 207 - 216 
(2003) [R17-2917]
9Ambrosy  AP, Pang PS, Khan S, Konstam MA, Fonarow GD, Traver B, Maggioni AP, 
Cook T, Swedberg K, Burnett Jr JC, Grinfeld L , James E. Udelson JE, Faiez Zannad F, 
Gheorghiade M . Clinical course and predictive value of congestion during 
hospi[INVESTIGATOR_676648] s ymptoms of heart failure 
with reduced ejection fraction: findings from the EVEREST trial
. European Heart 
Journal (2013) 34, 835–843 [ R19- 0744]
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 51of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
9. ADDITIONAL SECTIONS
9.1 REGIONS AND COUNTRIE S
Countries will be assigned to regions, as outlined in Table 9.1: 1.  
Table 9.1: [ADDRESS_915055]
Poland 
Portugal
Spain
Sweden
North America Canada
US
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 52of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
9.2 DIABETES STATUS AT B ASELINE
Patients will be assigned to diabetes status category , as outlined in Table 9.2:1 .  
Table 9.2: 1 DM at baseline
Diabetes status at 
baselineDefiniton
DM Patients who fulfil one of the following :
-investigator -reported medical history  of diabetes on the 
medical history page 
OR
-any pre-treatment HbA1c value >= 6.5%
Pre-DM Patient who fulfil all of the following:
-investigator reported ‘no’ for the medical history  of 
diabetes on the medical history  page 
AND
-a pre -treatment HbA1c value of >=5.7% and all pre -
treatment HbA1c <6.5%
Missing Patients who fulfil one of the following:
-missing assessment of history  of diabetes on the medical 
history  page AND all pre -treatment HbA1c <6.5%
OR
- no pre -treatment measurement of HbA1c AND 
investigator reported ‘no’ for the medical history  of 
diabetes on the medical history  page
OR
- no pre -treatment measurement of HbA1c and missing 
assessment of history  of diabetes on the medical history  
page
Non-DM (excl pre -DM) Patients not meeting the above criteria 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 53of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
9.3 DERIVATION OF RESPONDER THRESHOLD FOR KCCQ -TSS AND 
CHQ- SAS DYSPNEA
A minimal clinically  meaningful within patient -change in scores (i.e. responder threshold) 
will be estimated from the trial population (both treatment groups pooled) for KCCQ -TSS 
and CHQ -SAS Dy spnea using the below algorithm. All observed values will be co nsidered in 
this analy sis without imputation of missing values (OC -AD).
Anchor
The Patient Global Impression of Severity  (PGI -S) of Dy spnea and PGI -S of Heart Failure 
Symptoms will each be used as the primary  anchor for the CHQ -SAS Dy spnea scale and 
KCCQ -TSS, respectivel y. The Patient Global Impression of Change (PGI- C) of Dy spnea and 
PGI-C of Heart Failure Sy mptoms will be considered as secondary anchor scales for the 
CHQ -SAS Dy spnea scale and KCCQ -TSS, respectively .
A minimal clinically  meaningful improve ment for each PGI -S scale will be considered to be 
at least a one category  improvement in change from baseline in PGI -S at week 12.
A minimal clinically  meaningful improvement for each PGI -C scale will be considered to be 
at least “a little better” in PGI -C at week 12.
As an ancillary  consideration, the distance walked in [ADDRESS_915056] 30 meters from 
baseline in distance walked in 6 minutes will be considered to be clinical responders [ R17-
1227] (5 ).
Responder Threshold
To determine the threshold of the Patient Reported Outcome ( PRO )measure that best 
identifies patients with minimal clinically  meaningful difference as specified above 
(responders / non- responders), the following procedure will be applied:
A receiver operating characteristic (ROC) curve of change from baseline of the PRO measure
will be derived from the logistic regression model with the binary  anchor (at least one 
catego ry improvement in PGI -S Y/N) as dependent variable.
The mean of the cut
-offs closest to the balance point (i.e. where sensitivity  equals specificit y)
will be used as the responder threshold for each respective scale ’s PRO score.
For further anal ysis of the key  secondary  endpoint as defined in S ection [IP_ADDRESS] a patient will 
be considered a responder if the PRO score is greater than or equal t o the response threshold 
determined b y the anchor of one category improvement in corresponding PGI -S 
questionnaire. 
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 54 of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Graphical presentations
The ROC curve will be used to illustrate the ability of the PRO score to discriminate between
responders and non-responders. The area under the ROC curve (AUC) will be reported inaddition.
Descriptive empi[INVESTIGATOR_676649] (ECDF) will also be plotted by [CONTACT_676673].
Supportive Analyses
Distribution-based analyses will be performed for the CHQ-SAS Dyspnea scale and the
KCCQ-TSS on data of change from baseline to week [ADDRESS_915057] error of measurement (SEM) as well as 0.2*SD and 0.5*SD of the CHQ-SAS
Dyspnea scale and the KCCQ-TSS baseline measurement will be used as benchmarks [ R07-
1182](6).
The SEM is defined as   ∗√ (1− )with reliability coefficient r=0.88 for the KCCQ-TSS
(Cronbach’s alpha in [R17-2666] (7)) and r=0.91 for the CHQ-SAS Dyspnea (Cronbach’s 
alpha in [R17-2917] (8)).
For patients who achieved a one-category improvement in PGI-S Dyspnea at week 12 from 
baseline, the descriptive median (with inter-quartile range) of CHQ-SAS Dyspnea will be 
displayed by [CONTACT_676674]-S Dyspnea category. The table will be repeated separately for one-category deterioration, two-category improvement, two category deterioration, and no change 
in PGI-S dyspnea.
For patients who achieved a one-category improvement in PGI-S in heart failure symptoms at 
week 12 from baseline, the median (with inter-quartile range) of KCCQ-TSS will be displayed by [CONTACT_676674]-S in heart failure symptoms category. The table will be repeated 
for one-category deterioration, two-category improvement, two category deterioration, and no 
change in PGI-S in heart failure symptoms.
9.4 DERIVATION OF KCCQ AND CHQ-SAS DOMAINS
The following algorithm will be used to score the KCCQ-TSS and the CHQ-SAS Dyspnea.
9.4.1 Kansas City Cardiomyopathy Questionnaire (KCCQ)
There are 10 summary scores within the KCCQ, which are calculated as follows:
1. Physical Limitation
Code responses to each of Questions 1a-f as follows:
∀Extremely limited = 1
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 55of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Quite a bit limited = 2
Moderately limited = 3
Slightly  limited = 4
Not at all limited = 5
Limited for other reasons or did not do = <missing value>
If at least three of Questions 1a- f are not missing, then the Phy sical Limitation Score is 
calculated as follows:
Physical Limitation Score = 100*[(mean of Questions 1a -f actually  answered) – 1]/4
2.Symptom Stability
Code the response to Question 2 as follows:
Much worse = 1
Slightly  worse = 2
Not changed = 3
Slightly  better = 4
Much better = 5
I’ve had no s ymptoms over the last 2 weeks = 3
If Question 2 is not missing, then the S ymptom Stability  Score is calculated as follows:
Symptom Stability  Score = 100*[(Question 2) 
–1]/4
3.Symptom Frequency
Code responses to Questi ons 3, 5, 7 and 9 as follows:
Question 3
Every  morning = 1
3 or more times a week but not every  day = 2
1-2 times a week = 3
Less than once a week = 4
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 56of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Never over the past 2 weeks = 5
Questions 5 and 7
All of the time = 1
Several times a day  = 2
At least once a day  = 3
3 or more times a week but not every  day = 4
1-2 times a week = 5
Less than once a week = 6
Never over the past 2 weeks = 7
Question 9
Every  night = 1
3 or more times a week but not every  day = 2
1-2 times a week = 3
Less than once a week = 4
Never over the past 2 weeks = [ADDRESS_915058] two of Questions 3, 5, 7 and 9 are not missing, then the Symptom Frequency  Score 
is calculated as follows:
S3 = [(Question 3) – 1]/4
S5 = [(Question 5) – 1]/6
S7 = [(Question 7) – 1]/6
S9 = [(Question 9) –1]/4
Symptom Frequency  Score = 100*(mean of S3, S5, S7 and S9)
4.Symptom Burden
Code responses to each of Questions 4, 6 and 8 as follows:
Extremely  bothersome = 1
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 57of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Quite a bit bothersome = 2
Moderatel y bothersome = 3
Slightly  bothersome = 4
Not at all bothersome = 5
I’ve had no swelling/fatigue/shortness of breath = [ADDRESS_915059] one of Questions 4, 6 and 8 is not missing, then the S ymptom Burde nScore is 
defined as follows:
Symptom Burden Score = 100*[(mean of Questions 4, 6 and 8 actuall y answered) –1]/4
5.Total Symptom Score
The Total Sy mptom Score is defined as the mean of the following available summary  scores:
Symptom Frequency  Score and S ymptom Burden Score
6.Self-Efficacy
Code responses to Questions 10 and 11 as follows:
Question 10
Not at all sure = 1
Not ve ry sure = 2
Somewhat sure = 3
Mostly  sure = 4
Completely  sure = 5
Question 11
Do not understand at all = 1
Do not understand very  well = 2
Somewhat understand = 3
Mostly  understand = 4
Completely  understand = 5
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 58of 63
Proprietary confidential information © [ADDRESS_915060] one of Questions 10 and 11 is not missing, then the Self -Efficacy  Score is 
calculated as:
Self-Efficacy  Score = 100*[(mean of Questions 10 and 11 actuall y answered) –1]/4
7.Quality  of Life
Code responses to Questions 12, 13 and 14 as follows:
Question 12
It has extremely  limited my  enjo yment of life = 1
It has limited m y enjo yment of life quite a bit = 2
It has moderatel y limited my  enjo yment of life = 3
It has slightly  limited m y enjoyment of life = 4
It has not limited my  enjoy ment of life at all = 5
Question 13
Not at all satisfie d = 1
Mostly  dissatisfied = 2
Somewhat satisfied = 3
Mostly  satisfied = 4
Completely  satisfied = 5
Question 14
I felt that way  all of the time = 1
I felt that way  most of the time = 2
I occasionally  felt that way  = 3
I rarely
 felt that way  = 4
I never felt that way = [ADDRESS_915061] one of Questions 12, 13 and 14 is not missing, then the Qualit y of L ife Score is 
calculated as:
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 59of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Quality  of Life Score = 100*[(mean of Questions 12, 13 and 14 actuall y answered) –1]/4
8.Social L imitation
Code responses to each of Questions 15a- d as follows:
Severel y limited = 1
Limited quite a bit = 2
Moderately limited = 3
Slightly  limited = 4
Did not limit at all = 5
Does not appl y or did not do for other reasons = <missing value>
If at least two of Questions 15a -d are not missing, then the Social L imitation Score is 
calculated as:
Social L imitation Score = 100*[(mean of Questions 15a -d actually  answered) – 1]/4
9.Overall Summary  Score
The Overall Summary  Score is defined as the mean of the following available summary  
scores:
Physical Limitation Score, Total Sy mptom Score, Quality  of Life Score and Social L imitation 
Score
10.Clinical Summary  Score
The Clinical Summary  Score is defined as the mean of the following available summary  
scores:
Physical Limitation Score and Total Sy mpto m Score
Note: references to “means of questions actuall y answered” imply the following.
If there are n questions in a scale, and the subject must answer m to score the scale, but the 
subject answers only  n-i, where n -i >= m, calculate the mean of those questions as
(sum of the responses to those n
-i questions) / (n- i)
not
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 60of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
(sum of the responses to those n- i questions) / n
The change from baseline to week 12 in KCCQ -TSS will be calculated as the difference of the 
score at follow -up (week 12) and at baseline . 
9.4.2 Chronic Heart Failure Questionnaire (CHQ) Self- Administered 
Standardi sed format (SAS)
The CHQ -SAS dy spnea score is defined as the mean of Questions 1 -5 within the CHQ -SAS.
The CHQ -
SAS fatigue score is defined as th e mean of question 7, 9, 12, 14 .
The CHQ -SAS emotional function score is defined as the mean of questions 6, 8, 10, 11, 13, 15, 
16.
The scores for each question of each dimension are added together and divided by [CONTACT_676675]. Only  items that are answered will be scored. Th at is items that are scored as “not done” 
or missing will not be included in the summary (average) score. The average score of the 
completed items will be reported.
The change in the score of each domain will be calculated as the difference of the mean score at 
follow -up (week 12) and baseline.
9.5 DERIVATION OF CLINICAL CONGESTION SCORE
Following the scoring algorithm in Ambros y et al. the clinical congestion score is defined a 
summary  score of the 3 items jugular venous distension (JVD), orthopnea and e dema [R19-
0744
(9)] .
Code responses to orthopnea as follows:
None = 0
Seldom = 1
Frequent = 2
Continuous = 3
Code responses to JVD as follows:
‘≤ 6’ = 0
‘6<JVD<10’ = 1
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 61of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
‘10≤JVD<15’ = 2
‘≥15’ = 3
Code responses to Edema as follows:
absent/trace=0
Slight=1
Moderate=2
Marked=[ADDRESS_915062] two of the three items JVD, orthopnea and edema are not missing, then the Clinical 
Congestion Score is calculated as:
Clinical Congestion Score = (mean of items JVD, orthopnea and edema actually answered)*3
Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 62of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
10. HISTORY TABLE
This is a revised TSAP including the following modifications to the final TSAP
Table 10: 1 History table
Version Date
(DD-
MMM- YY)Author Sections 
changedBrief description of change
FINAL 5-APR -[ADDRESS_915063] -19 Section 6.3 / 
Section 7.4 / 
Section 7.5Definition of Senstivity analysis set 2 and 
Sensitivity analysis set 3
Reason for change:
For a subset of patients, on -treatm ent urine 
dipstick test results for urine glucose had been 
transferred from the central laboratory to the 
sites before DBL. A positive urine glucose test 
can be suggestive of treatment allocation. 
Therefore, an additional sensitivity analysis is 
performed based on the subset of patients who 
did not have an on -treatment urine glucose 
measurement transferred to and accessed by [CONTACT_676676].
In patients with diabetes mellitus at baseline, a 
positive urine dipstick test result is of limited 
value with respect to bearing potential 
information on treatment allocation. Therefore, a 
second additional sensitivity analysis is 
performed, which excludes those non -diabetic 
patients for whom at least one on -treatment 
urine glucose measurement was transferred to 
and accessed by [CONTACT_676677] D BL.
Reason for change:
Clarification.
Reason for change:

Boehringer Ingelheim
TSAP for BI Trial No: 1245-0168 Page 63of 63
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 10: 1 History table (cont.)
Version Date
(DD-
MMM- YY)Author Sections 
changedBrief description of change
Section 6.6 Clarification of 6MWTD if a patient performs 
the visit at week 12 but does not perform the 
6MWT.
Clarification of handling of missing baseline 
questionnaires for WCI analyses .
Clarification of handling of SAE with outcome 
“recovered with sequelae” leading to an 
amputation .
Reason for change: Clarifications consistent 
with protocol .
Section 6.7 Clarification of time windows for laboratory 
values at day of treatment start , repeated values ,
and time windows for sensitivity analyses using 
primary analysis model .
Reason for Change :
For laboratory values, clock time is recorded and
therefore can be taken into account .
All models using Wilcoxon will use the same 
time window
Section 7.8 AEs will be coded using version 22.0 of the 
MedDRA coding dictionary. 
Reason for Change :
Clarification
Section 8 Update of References
Reason for change :
References have been updated to the current 
versions of BI How  to guides 
Reason for change:
Clarification
